Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

as these are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Vertex basically reflects positivity about its earnings ...

But the real excitement lies in Vertex's push beyond CF, where years of investment are finally bearing fruit. All eyes are on Jan. 30, when the FDA weighs in on suzetrigine -- a potential game ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

“As Vertex scales for future growth, we continually evaluate our real estate portfolio to ensure ... space and headquarters to several prominent life science firms.